Associated Papers
Circulating Tumor DNA as a Biomarker for Precision Medicine in Prostate Cancer: A Systematic Review.
Chanhih N et al.
International Journal of Molecular Sciences, 2025
41303533 (PubMed )
Supplement: ijms-26-11049-s001.zip › Supp_M_Table_S7.pdf
Mutations in epigenetic regulator KMT2C detected by liquid biopsy are associated with worse survival in prostate cancer patients.
Zhu S et al.
Oncology Research, 2023
37415738 (PubMed )
Supplement: OncolRes-31-28321-s002.xlsx › Sheet1
Cell-Free DNA Sequencing Reveals Gene Variants in DNA Damage Repair Genes Associated with Prognosis of Prostate Cancer Patients.
Lieb V et al.
Cells, 2022
36429046 (PubMed )
Supplement: cells-11-03618-s001.zip › Suppl._files › Suppl._Table_S2_.xlsx › AR_variants
Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer.
De Sarkar N et al.
Jci Insight, 2021
34877933 (PubMed )
Supplement: jciinsight-6-152789-s069.xlsx › Table_S6
Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer.
Taavitsainen S et al.
Jco Precision Oncology, 2019
Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making.
Abida W et al.
Jco Precision Oncology, 2017
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.
Chen EJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2015
Select a paper to view details